Early-phase neuroscience trials have traditionally focused primarily on establishing safety and tolerability. From Alzheimer's disease to psychiatry, early development strategies can also generate ...

The Swiss startup is developing an AI foundation model that predicts drug efficacy and safety in virtual patients, ...

Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to ...

Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing, followed by ...

Gain strategic insight into 150+ BsADCs, clinical trial design, combination strategies, technology platforms, leading developers and China's dominant R&D landscape.Dublin, Oct. (GLOBE NEWSWIRE) -- ...

The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using ...

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to ...

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...

Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research Institute ...

OpenAI has acquired Orchestra Bio, folding its AI agent platform for managing drug programs into the Rosalind life sciences ...

The Drug Discovery and Development program provides in-depth exposure to the multiple elements involved in the discovery and development of marketed drugs. It provides the rigorous scientific and ...

OpenAI Group PBC revealed today that it has acquired drug development software startup Orchestra Bio Inc. Orchestra builds ...